Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Response to STRENSIQ
2022-502793-17-00Phase 4Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of asfotase alfa, rituximab, bortezomib, methotrexate and immune globulin in hypophosphatasia (HPP), sponsored by Alexion Pharmaceuticals. Primary endpoint: IST complete response at Week 100. Started Jan 2024; status: completed.
02
Drugs
asfotase alfarituximabbortezomibmethotrexateimmune globulin
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2022-502793-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502793-17-00.